Diabetes is a growing worldwide concern (425 million diabetics in 2017). It is a leading cause of death and its prevalence is increasing (19.2% rate). It requires long-life care management from a physician care team and patient daily self-management. Apps have been probed to improve diabetes self-care of patients, but the challenge is to identify a clinically validated one among the thousands existing. Our solution outperforms current state-of-the-art since we offer a (1) Class IIA, (2) AI powered that provides personal recommendations based on the individual’s lifestyle and regional context and (3) focus on end-user allowing connection with medical devices and fitness trackers.
We target the Diabetes Care Market, €69.10B in 2016, forecast to reach €137.28B by 2022, 12.4% CAGR. We aim to offer DIABETESMART to corporates (yearly tariff) and to diabetics Type 1, 1.5 and 2 (monthly subscription scheme) who will benefit from real-time clinically meaningful insights based on AI. We foresee to reach a gross profit of €9.65 million by 2026 with a ROI of 9.9€.